XML 55 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Segment and Geographic Information
 12 Months Ended
Apr. 24, 2020
Segment Reporting [Abstract]  
Segment and Geographic Information Segment and Geographic Information
The Company’s organizational structure is based upon four principal operating and reportable segments: the Cardiac and Vascular Group, the Minimally Invasive Therapies Group, the Restorative Therapies Group, and the Diabetes Group. The Company's management has chosen to organize the entity based upon therapy solutions provided by each segment. The four principal segments are strategic businesses that are managed separately, as each one develops and manufactures products and provides services oriented toward targeted therapy solutions.
The primary products and services from which the Cardiac and Vascular Group segment derives its revenues include products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease, as well as services to diagnose, treat, and manage heart- and vascular-related disorders and diseases.
The primary products and services from which the Minimally Invasive Therapies Group segment derives its revenues include those focused on diseases of the respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, obesity, and other preventable complications.
The primary products and services from which the Restorative Therapies Group segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat.
The primary products from which the Diabetes Group segment derives its revenues include those focused on diabetes management, including insulin pumps, continuous glucose monitoring systems, and insulin pump consumables.
Segment disclosures are on a performance basis, consistent with internal management reporting. Net sales of the Company's segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments. The Company's management evaluates the performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosures for the prior periods to align with the current presentation.
The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.
Segment Operating Profit
 Fiscal Year
(in millions)202020192018
Cardiac and Vascular Group$3,719  $4,532  $4,461  
Minimally Invasive Therapies Group3,044  3,262  3,346  
Restorative Therapies Group2,915  3,319  3,058  
Diabetes Group546  739  634  
Segment operating profit10,224  11,852  11,499  
Interest expense(1,092) (1,444) (1,146) 
Other non-operating income, net356  373  170  
Amortization of intangible assets(1,756) (1,764) (1,823) 
Corporate(1,239) (1,291) (1,211) 
Centralized distribution costs(1,420) (1,689) (1,936) 
Restructuring and associated costs(441) (407) (107) 
Acquisition-related items(66) (88) (132) 
Certain litigation charges(313) (166) (61) 
IPR&D charges(25) (58) (46) 
Exit of businesses(52) (149) —  
Debt tender premium and other charges7  28  —  
Divestiture-related items—  —  (115) 
Medical device regulations(48) —  —  
Contribution to Medtronic Foundation(80) —  (80) 
Gain on sale of businesses—  —  697  
Hurricane Maria—  —  (34) 
Income before income taxes$4,055  $5,197  $5,675  

Total Assets and Depreciation Expense
Total AssetsDepreciation Expense
(in millions)April 24, 2020April 26, 2019202020192018
Cardiac and Vascular Group$14,844  $15,453  $210  $194  $183  
Minimally Invasive Therapies Group39,666  41,186  194  206  217  
Restorative Therapies Group16,850  16,825  233  217  146  
Diabetes Group3,165  3,095  38  34  29  
Segments74,525  76,559  675  651  575  
Corporate16,164  13,135  232  244  246  
Total$90,689  $89,694  $907  $895  $821  
Geographic Information
Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. Geographic property, plant, and equipment are attributed to the country based on the physical location of the assets.
The following table presents net sales for fiscal years 2020, 2019, and 2018, and property, plant, and equipment, net at April 24, 2020 and April 26, 2019 for the Company's country of domicile, countries with significant concentrations, and all other countries:
Net salesProperty, plant, and equipment, net
(in millions)202020192018April 24, 2020April 26, 2019
Ireland$85  $91  $85  $164  $156  
United States14,919  16,194  15,875  3,459  3,122  
Rest of world13,909  14,272  13,993  1,205  1,397  
Total other countries, excluding Ireland28,828  30,466  29,868  4,664  4,519  
Total$28,913  $30,557  $29,953  $4,828  $4,675  
No single customer represented over 10 percent of the Company’s consolidated net sales in fiscal years 2020, 2019, or 2018.